In This Issue:
- President's Message
- Board of Director's Update
- Public Policy Update
- R & E Foundation Update
- Pharmacist Continuing Education Articles
- Safety and Efficacy of Anticoagulation Regimens in COVID-19
- Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
- Featured Clinical Topics:
- Role of Critical Care Clinical Pharmacists in Post-Intensive Care Syndrome Clinics
- Management of Abuse and Misuse Due to Unexpected Sources
- Glycoprotein IIb/IIIa Inhibitors: Remaining Clinical Roles
- Choice of Fluids for Initial Resuscitation in Patients with Septic Shock
- Affiliate Chapter News and Events
- Upcoming Newsletter Info
|
|
By Christina Stafford, PharmD, BCPS; MSHP President; CoxHealth, Springfield |
“When you can’t find the sunshine, be the sunshine.”- Unknown
“If you do something awesome, you should be proud of yourself.”- Damon Lindelof
“To plant a garden is to believe in tomorrow.” - Audrey Hepburn
Whew, what a year it has been!! As I reflect upon this past year, I cannot help but be overwhelmed by the continued resiliency and dedication displayed by our members.
|
|
Board of Director's Update |
|
Board Update
By: Nathan Hanson, PharmD, MS, BCPS
March
- Legislative Day preparations are on schedule. Pre-meetings are scheduled for 3/22 for students and 3/29 for membership to ensure participants are prepared. The opening address will be a partnership between MPA and MSHP as in previous years.
- Planning is underway for the Spring Meeting.
- MSHP has signed on with ASHP in support of a bipartisan pharmacist provider status bill. This bill would require Medicare Part B to reimburse pharmacists for testing, treatment, and vaccination against COVID-19, flu, RSV, and strep pharyngitis that would otherwise be covered if furnished by a provider.
- The New Practitioner Workgroup is seeking hiring managers to review CVs for new practitioners.
- The board discussed a variety of pending items, including website updates and awards.
April
- Celebrated a successful Legislative Day!
- Discussed ASHP House of Delegates policies
-
Planning for Spring Meeting and Strategic Planning retreat
|
|
Updates from the Capitol
By: Annie Kliewer, PharmD, BCPS
Hundreds of community and health-system based pharmacists came together in Jefferson City. On April 6th, we flooded the capitol with white coats, talking to our legislators about a variety of issues that greatly impact the practice of pharmacy and the care which we can provide our patients. Here is where each of the pharmacy/healthcare related bills of MSHP, MHA and MPA’s ended up by the conclusion of the 2022 MO Legislative session on May 13, 2022:
|
|
Research & Education Foundation Update: |
|
I want to start with a huge congratulations to all our R&E poster and award winners! Their contributions to our society and their research achievements are at the heart of the purpose of the R&E Foundation.
|
|
Tony Huke, Pharm.D., BCPS
MSHP R&E Executive Director
|
|
Safety and Efficacy of Anticoagulation Regimens in COVID-19
Author: John Love, Pharm.D, MBA
|
|
Program Number: 2022-05-03
Approved Dates: June 1, 2022-December 1, 2022
Approved Contact Hours: One Hour(s) (1) CE(s) per session
Learning Objectives
- Identify different dosage strategies for prophylactic anticoagulation in the setting of COVID-19.
- Summarize available data regarding different anticoagulation strategies in COVID-19.
- Recommend when therapeutic anticoagulation is appropriate in the setting of COVID-19.
|
|
Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
Authors: Kelly Knauer, PharmD; Ulyana Kucherepa, PharmD, PGY-1 Pharmacy Practice Residents
Mentor: Davina Dell-Steinbeck, PharmD, BCPS
|
|
Program Number: 2022-05-04
Approved Dates: June 1, 2022 - December 1, 2022
Approved Contact Hours: One Hour(s) (1) CE(s) per session
Learning Objectives
- Review current guideline recommendations on DAPT duration in patients undergoing percutaneous coronary intervention.
- Differentiate unique features of P2Y12 inhibitors
- Describe the results of existing evidence investigating DAPT duration after percutaneous coronary revascularization.
- Identify possible confounders to recent trials that may impact the external validity of the results
- Apply knowledge of patient considerations for P2Y12 inhibitors to results of recent literature to select an appropriate DAPT therapy for a patient after percutaneous coronary revascularization
|
|
Featured Clinical Topic:
Role of Critical Care Clinical Pharmacists in Post-Intensive Care Syndrome Clinics
|
|
By: Katelyn Kennedy, PharmD candidate 2022
Mentor: Kevin Betthauser, PharmD, BCCCP
|
|
In the United States each year there are more than 5 million intensive care unit (ICU) admissions.1 In the past 30 years, significant progress has been made to improve the outcomes for patients admitted to the ICU. From 1988 to 2012, mortality rates have decreased by 35%, thus creating an overall survival rate of roughly 80%. While encouraging, these positive trends have brought to light new challenges for healthcare providers and survivors of critical illness.
|
|
Featured Clinical Topic:
Management of Abuse and Misuse Due to Unexpected Sources
|
|
By: Destiny Knatt, PharmD Candidate and Gabrielle Gibson, PharmD, BCPS, BCCCP
|
|
Addiction is a serious problem that affects millions of Americans of all ages each year. Conversations about addiction and substance use often revolve around recreational drugs and alcohol, but there are many household items that that can be misused or abused. |
|
Featured Clinical Topic:
Glycoprotein IIb/IIIa Inhibitors: Remaining Clinical Roles
|
|
By: Eric Johnston, Pharm.D. Candidate1, Justin Alberts, Pharm.D. Candidate1, Shane Austin, Pharm.D., BCPS2, Anastasia L. Armbruster, Pharm.D., FACC, BCPS, BCCP1
1St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy
2Missouri Baptist Medical Center, St. Louis, MO
|
|
Introduction
Heart disease remained the leading cause of death in the United States in 2020 according to the Centers for Disease Control and Prevention.1 In the United States (U.S.), approximately every 40 seconds an individual experiences a heart attack.2 For the management of ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI), the recent 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization reaffirm the essential role of percutaneous coronary intervention (PCI) in improving clinical outcomes.3
|
|
Featured Clinical Topic:
Choice of Fluids for Initial Resuscitation in Patients with Septic Shock
|
|
By: Emily Stock, BS, PharmD Candidate 2023 – St. Louis College of Pharmacy at UHSP
Mentor: Paul Juang, PharmD, BCPS, BCCCP, FASHP, FCCM – Barnes-Jewish Hospital
Of all hospitalizations ending in death, sepsis is present in 30 to 50%. In the US, sepsis accounts for 250,000 deaths annually.1 According to the 2021 Surviving Sepsis Campaign International Guidelines for the Management of Sepsis, sepsis and septic shock are medical emergencies that necessitate immediate resuscitation and treatment.2
|
|
Greater Kansas City Society of Health-System Pharmacists (GKCSHP)
President: Kerra Cissne, PharmD, BCPS (kerra.cissne@gmail.com)
______________________________________________________________________
Mid-Missouri Society of Health-System Pharmacists (MMSHP)
President: Alexandria Stringberg, PharmD, BCPS (stringberga@health.missouri.edu)
_______________________________________________________________________
Saint Louis Society of Health-System Pharmacists (STLSHP)
STLSHP Member Engagement
If you are interested in becoming more involved in STLSHP, one of our committees might be right for you! The Membership committee helps to coordinate membership events and the Newsletter committee reviews and coordinates our local STLSHP newsletter (we are bringing it back 😊). Please contact Yvonne Burnett (Yvonne.burnett@uhsp.edu) if you are interested in becoming involved in one of these committees.
President: Yvonne Burnett, Pharm.D., BCIDP (Yvonne.Burnett@uhsp.edu)
_______________________________________________________________________
Southeast Missouri Society of Health-System Pharmacists (SEMSHP)
President: Janice Wesbecher (jbueter@sehealth.org)
|
|
Upcoming Featured Clinical Topics:
- July/August 2022: Cardiology/Anticoagulation
- Sept/Oct 2022: Special Populations (Geriatrics, Pediatrics, Women’s/Men’s Health)/Transitions of Care
- Nov/Dec 2022: ID/Vaccines
|
|
Newsletter Submission Deadlines:
- July/August 2022: Due June 27
- Sept/Oct 2022: Due August 22
- Nov/Dec 2022: Due October 24
|
|
Newsletter Submission Guidelines
- Pharmacists, pharmacy technicians, and pharmacy students in Missouri are eligible to submit content for publication in the MSHP Newsletter. Student submissions need to include pharmacist oversight.
- Submit content to the current Newsletter Committee Chair on or before the established deadlines.
- CE and Featured Clinical Topics must be approved by the Newsletter Committee Chair in advance of article submission, to prevent duplicates. Duplicate articles submitted without advanced approval may not be published.
- Recommended length of submissions for committee, affiliate, college/schools of pharmacy, and student chapter reports is half to one page in length.
- Recommended length of submissions for featured clinical topics is 1 to 2 pages, without references.
- Recommended length of CE articles is individualized, based on the amount of CE provided.
- Recommended length of submission for other categories is 1 to 2 pages.
|
|
MSHP Board of Directors & Committee Chairs |
|
2021-2022 Board Members
President:
President-Elect:
Immediate Past President:
|
|
2021-2022 Committee Chairs
Vendor Relations Board Liaison:
Membership Committee:
Public Policy Committee:
Newsletter Committee:
Education and Programming:
Website & Social Media:
|
|
If you have any questions, comments, or wish to submit an article to for MSHP Newsletter, please contact the Newsletter Committee Chair (Laura Challen) or another Newsletter Committee member.
2021-2022 MSHP Newsletter Committee Members
|
|
|
|
|
|
|
